Tuesday, February 22, 2011

Universal flu vaccine working well in early test — Dynavax

Dynavax Technologies Corp. said its universal flu vaccine candidate did well in Phase I testing last year, so the company is planning the next stage clinical trials.
Berkeley-based Dynavax (NASDAQ: DVAX) presented data from Phase Ia and Ib tests of the vaccine, N8295, at a vaccine conference in Geneva. The vaccine, Dynavax said, was “very safe and generally well tolerated” by the 54 test subjects.

No comments:

Post a Comment